CAS 178804-04-1 | Benzenamine, 4-(2-benzothiazolyl)-2-methyl- | CAS Number 178804-04-1

200,000+ products from a single source!

sales@angenechem.com

Product Categories

Home > Amines > 178804-04-1

178804-04-1 | Benzenamine, 4-(2-benzothiazolyl)-2-methyl-

CAS No: 178804-04-1 Catalog No: AG0026BR MDL No:MFCD00950805

Product Description

Catalog Number:

AG0026BR

Chemical Name:

Benzenamine, 4-(2-benzothiazolyl)-2-methyl-

CAS Number:

178804-04-1

Molecular Formula:

C14H12N2S

Molecular Weight:

240.3235

MDL Number:

MFCD00950805

IUPAC Name:

4-(1,3-benzothiazol-2-yl)-2-methylaniline

InChI:

InChI=1S/C14H12N2S/c1-9-8-10(6-7-11(9)15)14-16-12-4-2-3-5-13(12)17-14/h2-8H,15H2,1H3

InChI Key:

IDBCUMFOZBUJCL-UHFFFAOYSA-N

SMILES:

Nc1ccc(cc1C)c1nc2c(s1)cccc2

NSC Number:

674495

Properties

Complexity:

271

Compound Is Canonicalized:

Yes

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Defined Bond Stereocenter Count:

Exact Mass:

240.072g/mol

Formal Charge:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Isotope Atom Count:

Molecular Weight:

240.324g/mol

Monoisotopic Mass:

240.072g/mol

Rotatable Bond Count:

Topological Polar Surface Area:

67.2A^2

Undefined Atom Stereocenter Count:

Undefined Bond Stereocenter Count:

XLogP3:

3.9

Literature

Title	Journal
Nanoliposomes for encapsulation and delivery of the potential antitumoral methyl 6-methoxy-3-(4-methoxyphenyl)-1H-indole-2-carboxylate.	Nanoscale research letters 20110101
The role of aryl hydrocarbon receptor and crosstalk with estrogen receptor in response of breast cancer cells to the novel antitumor agents benzothiazoles and aminoflavone.	International journal of breast cancer 20110101
Synthesis, and biological evaluation of 2-(4-aminophenyl)benzothiazole derivatives as photosensitizing agents.	Bioorganic & medicinal chemistry 20100815
Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention.	BMC cancer 20090101
BRCA1 transcriptional activity is enhanced by interactions between its AD1 domain and AhR.	Cancer chemotherapy and pharmacology 20081101
Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines.	Breast cancer research and treatment 20080701
Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells due to CYP1-mediated metabolism.	Breast cancer research : BCR 20080101
BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells.	The Journal of biological chemistry 20060526
Microsphere-based protease assays and screening application for lethal factor and factor Xa.	Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines.	Journal of medicinal chemistry 20060112
Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells.	Drug metabolism and disposition: the biological fate of chemicals 20041201
The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate.	Current medicinal chemistry 20040401
Synthesis and SAR of 2-arylbenzoxazoles, benzothiazoles and benzimidazoles as inhibitors of lysophosphatidic acid acyltransferase-beta.	Bioorganic & medicinal chemistry letters 20040322
Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.	British journal of cancer 20030804
Halothane, a novel solvent for the preparation of liposomes containing 2-4'-amino-3'-methylphenyl benzothiazole (AMPB), an anticancer drug: a technical note.	AAPS PharmSciTech 20030601
DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.	British journal of cancer 20030224
Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.	British journal of cancer 20030210
In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles.	British journal of cancer 20020422
Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.	Molecular cancer therapeutics 20020201
Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs.	Journal of medicinal chemistry 20020131
Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole.	Molecular pharmacology 20020101
Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.	Journal of medicinal chemistry 20010426
Antitumour benzothiazoles. Part 15: The synthesis and physico-chemical properties of 2-(4-aminophenyl)benzothiazole sulfamate salt derivatives.	Bioorganic & medicinal chemistry letters 20010423
The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and related compounds.	Current medicinal chemistry 20010201